We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+20.93%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$952M
AUM Growth
+$119M
Cap. Flow
-$4.06M
Cap. Flow %
-0.43%
Top 10 Hldgs %
45.23%
Holding
168
New
60
Increased
16
Reduced
31
Closed
41

Top Buys

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$23.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$18.1M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$16.8M
4
TVTX icon
Travere Therapeutics
TVTX
+$16.1M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$15.4M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$48M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$31.8M
3
MNKD icon
MannKind Corp
MNKD
+$19.8M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$18.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 81.36%
2 Miscellaneous 16.85%
3 Consumer Staples 1.74%
4 Technology 0.04%
5 Industrials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANTH
76
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.6M 0.17%
59,807
+5,875
+11% +$149K
ELOS
77
DELISTED
Syneron Medical Ltd
ELOS
$1.59M 0.17%
+127,500
New +$1.51M
ENZ
78
DELISTED
Enzo Biochem, Inc.
ENZ
$1.58M 0.17%
+380,000
New +$1.3M
RCPT
79
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$1.47M 0.15%
+35,000
New +$1.5M
LUMO
80
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.42M 0.15%
+5,556
New +$1.7M
EXEL icon
81
CALL
Exelixis
EXEL
$14.1B
$1.42M 0.15%
+400,000
New +$2.72M
ANIP icon
82
ANI Pharmaceuticals
ANIP
$1.66B
$1.41M 0.15%
+45,000
New +$1.19M
DRRX
83
DELISTED
DURECT Corp
DRRX
$1.21M 0.13%
+90,706
New +$1.58M
EPZM
84
DELISTED
Epizyme, Inc
EPZM
$1.2M 0.13%
+52,602
New +$1.59M
AKAO
85
DELISTED
Achaogen Inc
AKAO
$928K 0.1%
+60,000
New +$1.04M
EOCN
86
Eocene Ltd. Ordinary Shares
EOCN
$3.88M
$860K 0.09%
+52
New +$974K
AGEN
87
Agenus
AGEN
$322M
$634K 0.07%
+10,190
New +$708K
VVUS
88
PUT
DELISTED
Vivus Inc
VVUS
$594K 0.06%
10,000
– –
RGEN icon
89
PUT
Repligen
RGEN
$9.86B
$579K 0.06%
45,000
-120,000
-73% -$1.72M
BLUE
90
DELISTED
bluebird bio
BLUE
$455K 0.05%
1,544
– –
GNMX
91
DELISTED
Aevi Genomic Medicine Inc
GNMX
$428K 0.05%
61,263
– –
BLRX
92
BioLineRX
BLRX
$12.2M
$399K 0.04%
+298
New +$490K
ILMN icon
93
Illumina
ILMN
$33.6B
$372K 0.04%
2,570
+514
+25% +$75.5K
MBOT icon
94
Microbot Medical
MBOT
$96.7M
$364K 0.04%
168
– –
WMGI
95
DELISTED
Wright Medical Group Inc
WMGI
$311K 0.03%
+10,000
New +$315K
XNPT
96
DELISTED
XENOPORT, INC.
XNPT
$258K 0.03%
50,000
– –
INSY
97
DELISTED
Insys Therapeutics, Inc.
INSY
$255K 0.03%
12,306
-4,860
-28% -$96.4K
LCI
98
DELISTED
Lannett Company, Inc.
LCI
$241K 0.03%
1,686
– –
SCAI
99
DELISTED
Surgical Care Affiliates, Inc.
SCAI
$230K 0.02%
7,472
-12,528
-63% -$405K
AGN
100
DELISTED
Allergan plc
AGN
$195K 0.02%
+945
New +$187K
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2014 Portfolio in Review

As of Q1 2014, Perceptive Advisors held 168 positions worth $952M, up 14% from $833M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors's Q1 2014 filing shows 60 new, 16 increased, 31 reduced and 41 closed positions. Its largest new stake was Heron Therapeutics: 1,762,426 shares worth $24.5M. The largest sale was Celgene Corp, an estimated $48M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Perceptive Advisors's largest Q1 2014 buy was Heron Therapeutics: 1,762,426 shares worth $24.5M.
  • Perceptive Advisors added most to Clovis Oncology, Inc. in Q1 2014, an estimated $10.4M increase.
  • Perceptive Advisors's biggest Q1 2014 reduction was Celgene Corp, cutting an estimated $48M.
  • Perceptive Advisors fully exited Aegerion Pharmaceuticals in Q1 2014, selling an estimated $31.8M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $952M portfolio in Q1 2014.
  • Perceptive Advisors opened 60 new positions and closed 41 in Q1 2014.
  • Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $952M.

Based on Perceptive Advisors's 13F filing for Q1 2014, filed 15 May 2014.